Noninvasive Assessment of Preclinical Atherosclerosis by Lane, Helen A et al.
Vascular Health and Risk Management 2006:2(1) 19–30
© 2006 Dove Medical Press Limited. All rights reserved
19
REVIEW
Abstract: Initially considered as a semipermeable barrier separating lumen from vessel wall,
the endothelium is now recognised as a complex endocrine organ responsible for a variety of
physiological processes vital for vascular homeostasis. These include the regulation of vascular
tone, luminal diameter, and blood flow; hemostasis and thrombolysis; platelet and leucocyte
vessel-wall interactions; the regulation of vascular permeability; and tissue growth and
remodelling. The endothelium modulates arterial stiffness, which precedes overt athero-
sclerosis and is an independent predictor of cardiovascular events. Unsurprisingly, dysfunction
of the endothelium may be considered as an early and potentially reversible step in the
process of atherogenesis and numerous methods have been developed to assess endothelial
status and large artery stiffness. Methodology includes flow-mediated dilatation of the
brachial artery, assessment of coronary flow reserve, carotid intimamedia thickness, pulse
wave analysis, pulse wave velocity, and plethysmography. This review outlines the various
modalities, indications, and limitations of available methods to assess arterial dysfunction
and vascular risk.
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The vascular endothelium
The endothelium has an important role in maintaining vascular homeostasis. Although
once considered simply as a semipermeable membrane, endothelial cells transduce a
wide range of physiological stimuli, and in response, produce a variety of signalling
molecules that exert autocrine and paracrine effects. The endothelium can therefore
be considered as an important endocrine organ (Vanhoutte et al 1989; Vane et al
1990), and is responsible for maintaining vasomotor tone, hemostasis and thrombosis,
inflammatory processes, platelet and leucocyte vessel-wall interactions, and
controlling vascular permeability. The equilibrium between vasodilatation and
vasoconstriction in regional vascular beds is largely controlled by the interaction
between endothelium-derived vasoactive mediators and the vascular smooth muscle
layer. Endothelial nitric oxide (NO), produced by constitutive activity of nitric oxide
synthase (eNOS) (Schini-Kerth 1999), is a potent vasodilator and one of the most
important regulators of vascular tone. In addition, NO is antiatherogenic, inhibiting
platelet aggregation, smooth muscle proliferation, expression of adhesion molecules,
and neutrophil aggregation (Vanhoutte et al 1989; Vane et al 1990). Arterial endothelial
dysfunction is a key, early, and potentially reversible, event in the process of
atherogenesis and is characterised by impaired NO bioavailability (Healy 1990; Ross
1993; Berliner et al 1995). Endothelial dysfunction causes impaired vasomotor
responses to various neurohumoral stimuli which may contribute to transient
myocardial ischemia, plaque rupture, thrombosis, and myocardial infarction (Maseri
et al 1978). Endothelial dysfunction has so far been described in association with
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many established cardiovascular risk factors such as active
and passive smoking, hypertension, hypercholesterolemia,
obesity, and type II diabetes (McVeigh et al 1992; Anderson,
Meredith, et al 1995; Treasure et al 1995; Goodfellow et al
1996; Williams et al 1996; Koller 2002; Williams et al 2002).
The extent of endothelial dysfunction and vasomotor
responsiveness correlates with the rate of progression of
atherosclerosis and cardiovascular events (Schachinger et
al 2000; Widlansky et al 2003). As such, endothelial function
has importance, not only in determining predisposition to
atherosclerotic disease, but also in determining prognosis
in clinically affected patients.
Clinical assessment of endothelial
function
Endothelial function can be measured in a variety of ways
using invasive and noninvasive techniques in the coronary
and peripheral circulation. The clinical examination of
endothelial function involves assessing the ability of the
endothelium to release NO in response to various exogenous
and endogenous stimuli. The quantity of NO released from
endothelial cells determines the degree of vasodilatation
detected in clinical studies, and thus arterial “health”.
Ludmer and collegues (1986) initially tested this concept
by infusing acetylcholine into coronary arteries at
angiography and measuring subsequent changes in arterial
diameter. In healthy arteries, infusion of acetylcholine
caused vasodilation, whereas vasoconstriction occurred in
the presence of a damaged endothelial lining. Further
evidence that the observed vasodilation was secondary to
NO release was derived from studies which blocked
dilatation using inhibitors of the L-arginine-NO pathway
(Hodgson and Marshall 1989; Lefroy et al 1993).
Subsequent studies using vasoactive pharmacological and
physiological agents have confirmed differences in dilatation
and endothelial responsiveness between healthy vessels and
atherosclerotic vessels (Gollino et al 1991; Yeung et al 1991).
Coronary angiography
Methods of assessment
Quantitative coronary artery angiography of the left anterior
descending artery and intracoronary doppler techniques have
been applied to measure coronary artery vaso-respon-
siveness in response to endothelium-dependent agonists
such as bradykinin and mechanical stimuli such as increased
flow. Quantitative angiography can assess coronary arterial
luminal diameter following cardiac catheterization, whilst
doppler probes evaluate blood flow velocity in response to
infusion of vasoactive agents (Groves et al 1995).
The integrity of coronary arteries has recently been
evaluated angiographically via stimulation of the sym-
pathetic nervous system using exercise and cold pressor
tests. Sympathetic neuronal stimulation using cold pressor
testing induces vasodilatation in healthy vasculature and
vasoconstriction in proatherogenic disease states and
atherosclerotic coronary arteries (Zeiher et al 1991; Antony
et al 1994; Nitenberg et al 1998).
Although the coronary angiography technique is
undoubtedly a useful tool for assessing vascular risk,
widespread use is not practical. Coronary angiography is
invasive and unsuitable for studying early preclinical
atherosclerosis in asymptomatic subjects, or for the serial
evaluation of vascular physiology in response to potential
antiatherogenic strategies. Furthermore, its use is limited
as a consequence of serious adverse reactions reported
following the intracoronary infusion of acetylcholine at
angiography (Tio et al 2002).
Association with coronary artery disease and
atherosclerotic risk factors
Impaired vascular reactivity in the coronary artery
circulation is associated with traditional coronary risk factors
such as type 2 diabetes, insulin resistance, hypertension,
and dyslipidemia (Nitenberg et al 1998; Dagres et al 2004;
Mokelke et al 2005), even in the absence of clinically overt
atherosclerotic lesions. Impaired vascular reactivity may also
serve as an index integrating the overall stress imposed by
coronary risk factors (Vogel and Corretti 1998). Coronary
endothelial vasodilator dysfunction persists after angio-
graphically significant coronary atherosclerotic plaque is
evident and has been shown to predict long-term disease
progression and cardiovascular event rates in patients at risk
of coronary disease (Schachinger et al 2000). However,
disease modifying agents which reduce cholesterol and
exhibit antioxidant qualities improve coronary artery
endothelium-dependent dilatation (Anderson, Meredith, et
al 1995; Treasure et al 1995) and may reflect the
cardioprotective qualities of these agents.
Flow-mediated dilatation
Method of assessment
A noninvasive technique using high-resolution ultrasound
to overcome the practical constraints of invasive coronary
artery testing has been developed to assess endothelial
function in the peripheral circulation (Celermajer et al 1992).Vascular Health and Risk Management 2006:2(1) 21
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Using this technique, changes in brachial artery diameter
are measured by following the endothelium-dependent
stimulus of increased blood flow and may be compared with
changes in vessel diameter following the oral administration
of endothelium-independent agonists such as glyceryl
trinitrate (GTN) (Celemajer et al 1992). Since endothelial
dysfunction is a generalized systemic process, it occurs in
both the coronary and systemic circulation (Anderson,
Gerhard, et al 1995). Indeed, a close relationship has been
demonstrated between vasodilator responses in the brachial
artery and those in the coronary circulation (Anderson,
Uehata, et al 1995; Matsuo et al 2004). The sensitivity of
the original technique developed by Celermajer et al (1992)
has been improved by using a validated computerized vessel
wall tracking system (Vadirec Medical Systems
® [Ramsey
et al 1995]) to follow changes in brachial artery diameter
throughout the cardiac cycle.
Many wall tracking systems have been developed to
determine flow-mediated dilatation (FMD). One such
system comprises an adapted duplex colour flow echo
machine, giving high axial resolution (Ramsey et al 1995).
With this technique, the brachial artery is identified using
an ultrasound transducer with a stand-off device containing
ultrasound coupling gel placed between the transducer and
the arm to prevent compression of the anterior wall of the
artery. Vessel wall movements are tracked using the stored
radio frequency signals to produce displacement waveforms
of the anterior and posterior walls together with the
distension waveform (diameter change as a function of time
[Hoeks et al 1990]). The distension waveform allows
measurement of end-diastolic diameter for each beat,
providing a theoretical resolution of 3 m. Forearm blood
flow is measured throughout the study using a continuous
wave doppler probe positioned over the brachial artery
(Smith et al 2002). Once baseline measurements of brachial
artery diameter are established, a cuff placed at the wrist is
inflated to suprasystolic pressure, causing relative hand
ischemia. Release of the occluding cuff results in reactive
hand hyperemia and an associated increase in blood flow
through the brachial artery, which induces shear stress on
the arterial wall and provides a stimulus for endothelium-
dependent dilatation. Similar measurements can also be
made using a NO donor, eg, glyceryl trinitrate (GTN) for
an assessment of endothelial-independent vasodilatation
(Celermajer et al 1992).
A degree of investigator expertise is required to
determine brachial artery vasodilation using ultrasonography
and no consensus exists regarding the degree of vasodilation
which should be expected in individuals with healthy
endothelial function (Faulx et al 2003). Significant changes
in brachial artery reactivity have been reported within
healthy subjects throughout the course of a day when
measured by the same operators, suggesting that variability
occurs between morning and evening measurements, in
addition to variability between subjects examined on
different days (De Roos et al 2003). However, this is disputed
by others who have carefully controlled for confounding
factors (ter Avest et al 2005). Despite this, FMD will continue
to be an extensively used technique for assessing endothelial
function. Improvements in available equipment and operator
expertise will reduce variability in results.
Association with coronary artery disease and
atherosclerotic risk factors
The FMD technique is now one of the most widely used
noninvasive methods of assessing endothelial function and
closely correlates with cardiovascular risk (Kuvin and Karas
2003). Impaired FMD is described in insulin resistant states
and type 2 diabetes, dyslipidemia, hypertension, end stage
renal disease, and smoking (Yildiz et al 2003; Esen et al
2004; Holay et al 2004; Thomas et al 2004). Subsequently,
FMD has been used extensively to assess the potential
antiatherogenic qualities of treatment options, and continues
to be indispensable in determining endothelial integrity.
Carotid intimamedial thickness
Method of assessment
Another noninvasive method of assessing subclinical
atherosclerosis involves measurements of carotid intima-
media thickness (IMT) with high resolution B-mode
ultrasonography. This is a well established technique which
has been extensively used to estimate coronary artery events
and the extent of established atherosclerosis in central and
peripheral vasculature (Bots et al 1993), with early increases
in IMT possibly reflecting adaptation to elevated intra-
vascular shear stress (Bots et al 1997). As a noninvasive
imaging technique, quantitative carotid IMT is versatile for
use in large populations with minimal risk to subjects (Barth
2004). However, accurate measurements, particularly of the
near wall, require a high level of technical expertise.
Consequently, some authors suggest the administration of
contrast media during the examination period (Macioch et
al 2004; Martin and Lekaris 2004).
A variety of techniques have been used in the
determination of carotid IMT. Measurements of the commonVascular Health and Risk Management 2006:2(1) 22
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carotid, internal carotid, and carotid bifurcation are all
technically acceptable, including combination measure-
ments of 12 carotid arterial sites, eg, using Meijer’s Arch
(Bots et al 2003). In view of the diversity and lack of
uniformity in determining carotid IMT, meta-analysis
suggests that circumferential scanning of the carotid artery
and calculation of the mean maximum carotid IMT provides
a more accurate measurement of carotid atherosclerosis
(Bots et al 2003). However, all sites of carotid IMT
measurement appear to have equivalent value in predicting
future coronary artery events (Iglesias del Sol et al 2002).
Association with coronary artery disease and
atherosclerotic risk factors
Carotid IMT correlates with cardiovascular risk factors such
as the ‘metabolic syndrome’ (McNeill et al 2004), insulin
resistance in type 1 and 2 diabetics (Fujiwara et al 2003;
Singh 2003), microalbuminuria (Jadhav and Kadam 2002),
hypercholesterolemia (Wendelhag et al 1992), and
atherogenesis (Salonen and Salonen 1993).
Carotid IMT and the progression of IMT correlates well
with cardiovascular and cerebrovascular end-points (Bots
et al 1997; Hodis et al 1998; O’Leary et al 1999). However,
although extensive data supports the use of carotid IMT as
a predictor of cardiovascular risk, endothelial dysfunction
manifesting as impaired brachial artery reactivity may be
an earlier predictor of coronary artery disease, with increased
carotid IMT being evident at a later stage in the process of
atherogenesis (Furumoto et al 2002).
Cardiovascular risk and vascular
stiffness
Large artery stiffness
Arteriosclerosis is an integral part of the aging process
(Pearson et al 1994) and is now also recognised as an
important and independent risk factor for cardiovascular
disease (Arnett et al 1994). As a result of vascular stiffening,
the diastolic blood pressure decreases and pulse pressure
widens, as occurs with advancing age (Franklin et al 1997).
Consequently, brachial artery pulse pressure is a surrogate
marker of vascular stiffness and is used to determine
cardiovascular risk in normotensive and hypertensive
subjects (Benetos et al 1997, 1998; Franklin et al 1999),
having a higher predictive value of cardiovascular risk than
mean arterial blood pressure (Domanski et al 1999; Miller
et al 1999). Isolated systolic hypertension and elevated pulse
pressure have also been identified as a major cardiovascular
risk factor in the Systolic Hypertension in the Elderly
Programme and the Systolic Hypertension in Europe trial
(Frishman 2000).
Confirming the association between pulse pressure and
cardiovascular risk, Philippe et al (2002) demonstrated a
direct correlation between aortic pulse pressure, measured
with intra-aortic balloons at coronary angiography, and the
extent of atherosclerotic disease. Wave reflection within the
vascular tree leads to a higher pulse pressure in central
vessels than in the periphery (Pauca et al 1992; Nichols and
O’Rourke 1998, 2005). The resulting increase in left
ventricular after-load increases myocardial oxygen
consumption and promotes left ventricular hypertrophy. In
addition, increasing systolic pressure elevates arterial wall
circumferential stress and predisposes to atherosclerotic
plaque generation. Left ventricular hypertrophy that arises
from increased aortic systolic pressure (Lakatta 1991)
predisposes to coronary artery disease (MacMahon et al
1990), cerebrovascular events (Kannel et al 1981), and is
an independent predictor of cardiovascular mortality (Levy
et al 1990). Furthermore, increased arterial stiffening has
also been demonstrated in subjects with increased
cardiovascular risk including diabetes mellitus (Wahlqvist
et al 1988, Salomaa et al 1995), hypertension (McVeigh et
al 1991, Armentano et al 1991), hypercholesterolemia (Dart
et al 1991, Giannattasio et al 1996), and end stage renal
disease (Blacher et al 2002).
Regulation of large artery stiffness
Elastin and collagen are the major determinants of large
artery stiffness, with smooth muscle originally thought to
play a minor role (Wilkinson and McEniery 2004).
Advancing age causes gradual destruction in arterial wall
elasticity, with increasing demands placed on the collagenous
element (O’Rourke 1976; Avolio et al 1983). This
redistribution of the heterogeneous element in the vascular
wall can be triggered by endothelial dysfunction (Nili et al
2002). However, recent work has highlighted the importance
of smooth muscle in determining vessel stiffening.
Vasoconstrictors such as noradrenaline can increase vascular
stiffness and dilators such as hydrallazine and sodium
nitroprusside have the opposite effect (Nichols and O’Rourke
2005). Such vasoactive pharmacological agents can alter
vessel diameter by up to 30%, independent of changes in
peripheral resistance or blood pressure (Latson et al 1988),
demonstrating the important dynamic contribution of
vascular smooth muscle to large vessel stiffness.Vascular Health and Risk Management 2006:2(1) 23
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Whilst NO profoundly alters basal arterial tone, its effect
on arterial stiffness remains unclear. However, the acute
administration of a NO donor such as GTN produces
changes in the peripheral pressure pulse that are consistent
with a reduction in arterial stiffness (Cockcroft et al 1997).
β-adrenergic drugs, in particular albuterol, act via the
L-arginine-NO pathway to stimulate NO release and cause
vasodilatation in resistance arteries (Cardillo et al 1997;
Dawes et al 1997) via their action on β2-adrenoreceptors.
β2-agonists have therefore been used to evaluate endothelial
integrity in healthy controls (Hayward et al 2002).
Clinical assessment of arterial
stiffness
Pulse wave analysis and pulse wave
velocity
Method of assessment
The peripheral pressure waveform can be useful in
determining cardiovascular risk. However, an adequate
assessment of central arterial pressure waveforms cannot
be determined from peripheral pulse wave analysis (PWA)
because changes in vessel stiffening throughout the vascular
tree causes location-dependent changes in the pressure
waveform. In addition, central arterial waveforms will be
influenced by the reflective wave phenomenon as described
by Nichols and O’Rourke (2005). The systolic waveform
leaves the aortic root and travels to the periphery, where
smaller arterioles provide multiple points of reflection. A
resulting ‘reflective’ wave is generated and returns to central
arteries (O’Rourke and Kelly 1993). In individuals with
healthy compliant arteries, the reflective wave will return
to the central vasculature in diastole and augment diastolic
coronary arterial blood flow. The speed of the advancing
wave is termed pulse wave velocity (PWV) (Lehmann et al
1997). With age, a combination of increased reflective
capacity at peripheral sites and faster PWV within stiffened
vessels causes premature augmentation of the systolic
waveform, forming a ‘late systolic peak’ on waveform
analysis (Figure 1). This explains the differences between
the brachial and aortic pressure waveforms, which may be
as high as 20 mmHg (Pauca et al 1992). The central pressure
waveform is important in view of determining left
ventricular workload, which is relatively independent of the
brachial pressure.
In view of the above observations, a technique has been
derived by O’Rourke and Gallagher (1996), which is able
to noninvasively record the peripheral pulse pressure wave
and generate a corresponding central arterial waveform. The
technique involves the use of an applanation tonometer to
record the radial pulse wave. Applanation tonometry causes
partial flattening of the arterial wall and equilibration of
intra-arterial circumferential pressure. The accuracy of
arterial tonometry in recording peripheral waveforms has
been described by previous investigators who evaluated
waveforms derived from noninvasive tonometry and direct
arterial puncture (Cohn et al 1995). The central arterial
waveform can subsequently be derived from the peripheral
waveform using a validated generalized transfer factor
(Karamanoglu et al 1993; Chen et al 1997; Takazawa et al
1998; Fetics et al 1999). This is then expressed in terms of
an Augmentation Index (AIx) which can be used to assess
vascular stiffness and cardiovascular risk between study
groups.
Pulse wave analysis has more recently been used as a
noninvasive tool to assess endothelial function (Wilkinson,
Hall, et al 2002). Administration of β-agonist therapy
induces repeatable reductions in the AIx, which are inhibited
by infusion of L-NG-monomethyl arginine (L-NMMA),
suggesting that observed differences are endothelial- and
NO-dependent (Wilkinson, Hall, et al 2002). Nitroglycerin
administration induces further reductions in the AIx which
are unaffected by L-NMMA and thus endothelial-
independent (Wilkinson, Hall, et al 2002). Furthermore, the
technique has been shown to correlate with FMD in healthy
and type 2 diabetic subjects (Wilson et al 2004).
The analysis of PWV uses a similar system that
calculates pulse wave propagation velocity between two
sites, commonly the carotid and femoral pulses, or carotid
and radial (Oliver and Webb 2003), although brachial-ankle
PWV has been assessed by some (Katayama et al 2004;
Igarashi et al 2005). Pulse wave velocity is inversely
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proportional to vessel stiffness and distensibility (Nichols
and O’Rourke 2005). Waveform data is recorded from two
sites using noninvasive tonometry and stored electronically.
Following documentation of the distance between the two
recording sites, determination of the pulse transit time allows
calculation of PWV. In order to assess pulse transit time a
correlation point is identified within the pressure waveform,
which may be the foot of the pressure wave (using
SphygmoCor system) or the point of maximal upstroke
(using Complior system) (Millasseau et al 2005). If the two
pressure waveforms are not recorded simultaneously, an
R wave on the electrocardiograph can be used to calculate
wave transit time. Elevation of PWV leads to augmentation
of the ascending aortic systolic waveform as previously
outlined, resulting in higher left ventricular afterload and
amplification of pulse pressure (Nichols 2005).
Pulse wave analysis and PWV are both noninvasive
simple techniques that can be used to assess vascular
stiffness in research and clinical settings (O’Rourke and
Gallagher 1996; Hayward et al 2002; Sutton-Tyrrell et al
2005). Both techniques are influenced by factors that may
confound data. For example, elevation in pulse rate will
lower the AIx as a result of a reduction in reflective wave
amplitude, and does not represent a change in vascular
stiffness (Wilkinson, Mohammed, et al 2002). Consequently,
a correction factor has been suggested to standardize for
variation in heart rate (Wilkinson et al 2000). In addition,
an inverse relationship between AIx, PWV, and height has
been described, which may result from shorter reflective
wave propagation time in individuals with short stature
(McGrath et al 2001). While some investigators consider
this a confounding variable in data analysis, it may explain
the elevation in cardiovascular risk observed in short
individuals (Kannam et al 1994). Despite the lack of data to
confirm correlation between noninvasive and invasive
measurements of PWV (Chiu et al 1991; Davies and
Struthers 2003), the evidence that tonometer-derived PWV
is an important determinant of cardiovascular risk is difficult
to dispute.
Association with coronary artery disease and
atherosclerotic risk factors
Pulse wave analysis has revealed accelerated large artery
stiffening and endothelial dysfunction in association with
several well established cardiovascular risk factors such as
obesity (Suh et al 2005), end-stage renal failure (Covic et al
2003), and hypercholesterolemia (Wilkinson, Prasad, et al
2002). Similarly, PWV is increased in microalbuminuria
(Smith et al 2005), renal dysfunction (Haydar et al 2004),
type 2 diabetes (Tsuchiya et al 2004), and insulin resistance
(Sengstock et al 2005).
Using PWA and PWV, vascular stiffness has been
assessed and identified as an independent risk marker for
cardiovascular mortality (Laurent et al 2001; Meaume et al
2001) and cerebrovascular events (Laurent and Boutouyrie
2005), and has a prognostic value equivalent to currently
available biomarkers.
Elevations of central systolic pressure and consequent
proatherosclerotic effects can be modified by vasodilatory
compounds which reduce PWV in peripheral vessels without
altering brachial blood pressure. Such reductions in
augmentation of central pressure may underlie the observed
benefits of cardiovascular drugs which are not currently
attributed to blood pressure modification (Nichols 2005).
Vascular stiffness has consequently gained increasing
importance as a therapeutic target.
Photophlesymographic assessment of
pulse wave reflection
Method of assessment
Photophlethysmography involves measuring the digital
volume pulse via infrared light transmission through the
finger. Previous investigators have demonstrated that the
digital volume pulse resembles the carotid pressure wave
and alters in a similar way to vasoactive mediators
(Takazawa et al 1998). Reflected peripheral waveforms
cause a second peak in the digital volume pulse (DVP) in a
similar fashion to that seen in the peripheral pressure
waveform, as measured using PWA (Chowienczyk et al
1999). With this technique, the point at which the reflective
wave meets the systolic waveform is termed the inflection
point (IP). When suprasystolic pressure is applied to both
lower limbs at thigh level, the reflective wave returns sooner
and causes an expected elevation of the IP (Chowienczyk
et al 1999). In a similar way to the peripheral pressure wave,
the DVP undergoes changes in response to exogenous NO
donors such as GTN (Morikawa 1967; Lund 1986), which
is independent of changes in heart rate (Chowienczyk et al
1999). Using both techniques, the major change seen is a
reduction in the diastolic component of the waveform and
the preceding IP (Chowienczyk et al 1999). This has been
demonstrated recently in vivo, where acetylcholine-induced
endothelial-derived NO release resulted in lowering of the
IP in the photophlethysmographic waveform recorded inVascular Health and Risk Management 2006:2(1) 25
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cholesterol-fed rabbits. This response is diminished in
cholesterol-fed rabbits when compared with healthy rabbits
and antagonised by NOS inhibitors (Klemsdal et al 1994).
As with PWA, pharmacological preparations which induce
NO release, such as β-adrenergic drugs, will also cause a
reduction in the IP of the pulse volume waveform
(Chowienczyk et al 1999). Such effects are blunted by
L-NMMA administration which suggests that this effect
involves the L-arginine-NO pathway (Chowienczyk et al
1999).
Association with coronary artery disease and
atherosclerotic risk factors
With evidence supporting the use of this technique to assess
both endothelial-dependent and endothelial-independent
vasodilatation, investigators have studied patient groups who
are known to demonstrate marked endothelial dysfunction.
Photophlethysmographic examination of type 2 diabetics
has shown impairment of albuterol-induced responses with
preservation of the endothelial-independent vasodilatation
seen with GTN (Chowienczyk et al 1999). Vascular stiffness
using this technique has also been described in cases of
impaired glucose tolerance (Ohshita et al 2004) and
hypertension in aging individuals, although some authors
believe the technique to be inferior to PWV (Bortolotto et
al 2000). However, this noninvasive technique provides a
useful method of assessing vascular stiffening, in which both
endothelial-dependent and independent responses can be
determined (Millasseau et al 2002).
Biomarkers of endothelial function
As outlined previously, the antiatherogenic functions of the
endothelium are complex. Several biochemical markers have
been identified that correlate with coronary artery disease
and conventional cardiovascular risk factors (Szmitko et al
2003). Further investigation of the inflammatory and
thrombotic processes involved in atherogenesis will allow
the assessment of potential biomarkers which may be
incorporated into current cardiovascular risk stratification
models. Such biomarkers include, oxidized low-density
lipoprotein (oxLDL), high sensitivity C-reactive protein
(CRP), endothelial progenitor cells (EPC), prothrombotic
factors such as von Willebrand factor (VWF), and
inflammatory markers including tumor necrosis factor-α
(TNF-α), interleukin-6 (IL-6), and intracellular adhesion
molecule-1 (ICAM-1) (Ridker et al 2001; Szmitko et al
2003). The clinical use of many of the biomarkers is
restricted due to lack of end-point data (Tsimikas and
Witztum 2001), with the exception of CRP which may
correlate to a greater extent than traditional risk factors such
as LDL-cholesterol (Ridker et al 2005). In consequence,
CRP has already been incorporated into some risk
stratification models.
Oxidized LDL
Oxidation of LDL occurs within the subendothelial cells of
the vascular tissue which promotes the binding and
transformation of monocytes to foam cells (Parhami et al
1993; Watson et al 1997). Mechanisms include enhancing
chemotaxis and monocyte adhesion, upregulation of
inflammatory genes and growth factors, causing endothelial
cell dysfunction and apoptosis, enhancing platelet
aggregation with thrombus formation, and inducing plaque
destabilisation (Berliner et al 1995; Aikawa et al 1998;
Norata et al 2002). Consequently, oxLDL levels are
increased in cases of acute coronary syndrome and
myocardial infarction (Tsimikas et al 2003).
Prothrombotic factors
The prerequisites for thrombogenesis in atheromatous
plaques include activation of the coagulation cascade and
platelet activation (Smith et al 2003). As such, prothrombotic
factors are often evaluated in studies aimed at assessing
cardiovascular risk. von Willebrand factor is a multimeric
glycoprotein that is synthesised in endothelial cells and
released following endothelial damage (Mannucci 1998).
As such, levels can be indicative of the degree of endothelial
injury and subsequent atherosclerotic potential (Mannucci
1998). Prospective trials suggest that elevated VWF may
predict future cardiovascular events in patients with
established coronary atherosclerosis (Jansson et al 1991;
Thompson et al 1995), which may be a reflection of the
role of VWF in initiating platelet aggregation and thrombus
formation (Mannucci 1998). von Willebrand factor also has
a role in stabilising factor VIII and the latter, together with
fibrinogen, have been incorporated into cardiovascular risk
profiles in numerous studies (Wilhelmsen et al 1984; Folsom
et al 1999; Chambless et al 2003; Chaves et al 2004).
Endothelial progenitor cells
Endothelial progenitor cells have also gained importance
as a potential surrogate marker of endothelial health
(Schmidt-Lucke et al 2005). These are essentially stem cellsVascular Health and Risk Management 2006:2(1) 26
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which are recruited to sites of endothelial injury in order to
perform a therapeutic function by differentiating into mature
endothelial cells (Szmitko et al 2003). Depletion of
circulating EPCs with impaired adhesion to vasculature may
reflect repeated and enhanced demand for EPC mobilization
from bone marrow, and indicate a state of endothelial
dysfunction predisposing to enhanced cardiovascular risk
(Hill et al 2003). In support of this, reduced EPC levels
with impaired activity have been demonstrated in subjects
known to have impaired endothelial function, such as
hypertension and ischemic heart disease (Vasa et al 2001)
and their use for therapeutic intervention of vascular
dysfunction continues to be evaluated (Silva et al 2005).
Inflammatory markers
Several inflammatory markers have been described in
association with cardiovascular risk, including TNF-α,
IL-6, ICAM-1, and CRP, of which CRP has greatest
prognostic value (Ridker et al 2001; Ridker 2002). CRP is
not only a marker of cardiovascular risk, but may itself
function as a proatherogenic molecule (Szmitko et al 2003).
The acute phase reactant has been demonstrated to enhance
proinflammatory cytokines, such as IL-6, TNF-α, and
monocyte chemoattractant protein-1 (MCP-1), promoting
chemotaxis and lipid accumulation (Verma, Li, et al 2002;
Li and Fang 2004). In addition, CRP may interfere with
NO synthesis, inhibit angiogenesis, and influence vascular
remodelling (Verma, Wang, et al 2002; Wang et al 2003).
Although CRP correlates well with atherogenesis, it is
feasible that elevation reflects the impact of traditional risk
factors on inflammatory processes, as opposed to the direct
influence of CRP on endothelial function (Vita et al 2004;
Verma et al 2004).
Summary
As the number of individuals suffering from the ‘metabolic
syndrome’ escalates, the cardiovascular morbidity and
mortality rates of future generations may continue to rise
despite advances in pharmaceutical interventions. Disruption
of endothelial function is multifactorial and complex, and
precedes clinically apparent coronary and cerebrovascular
disease.
Therefore, the evaluation of reproducible, noninvasive
techniques for assessing endothelial function should enable
screening of large populations and may guide interventions
designed specifically to reduce the individual’s vascular risk.
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